282 related articles for article (PubMed ID: 30268859)
21. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism.
Robin P; Le Roux PY; Tromeur C; Planquette B; Prévot-Bitot N; Lavigne C; Pastre J; Merah A; Couturaud F; Le Gal G; Salaun PY
Thromb Res; 2017 Nov; 159():48-51. PubMed ID: 28978463
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of routine (18)F-FDG PET/CT in high-risk patients with gram-positive bacteremia.
Vos FJ; Bleeker-Rovers CP; Kullberg BJ; Adang EM; Oyen WJ
J Nucl Med; 2011 Nov; 52(11):1673-8. PubMed ID: 21984799
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of CT screening in the National Lung Screening Trial.
Black WC; Gareen IF; Soneji SS; Sicks JD; Keeler EB; Aberle DR; Naeim A; Church TR; Silvestri GA; Gorelick J; Gatsonis C;
N Engl J Med; 2014 Nov; 371(19):1793-802. PubMed ID: 25372087
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules.
Gould MK; Sanders GD; Barnett PG; Rydzak CE; Maclean CC; McClellan MB; Owens DK
Ann Intern Med; 2003 May; 138(9):724-35. PubMed ID: 12729427
[TBL] [Abstract][Full Text] [Related]
25. An economic evaluation of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence.
Auguste P; Barton P; Hyde C; Roberts TE
Health Technol Assess; 2011 Apr; 15(18):iii-iv, 1-54. PubMed ID: 21524363
[TBL] [Abstract][Full Text] [Related]
26. Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? - From Chinese healthcare system perspective.
Wang YT; Huang G
Eur J Radiol; 2012 Aug; 81(8):e903-9. PubMed ID: 22698711
[TBL] [Abstract][Full Text] [Related]
27. Revisiting occult cancer screening in patients with unprovoked venous thromboembolism.
Robin P; Carrier M
Thromb Res; 2018 Apr; 164 Suppl 1():S7-S11. PubMed ID: 29703487
[TBL] [Abstract][Full Text] [Related]
28. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
[TBL] [Abstract][Full Text] [Related]
29. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer.
Ghaneh P; Hanson R; Titman A; Lancaster G; Plumpton C; Lloyd-Williams H; Yeo ST; Edwards RT; Johnson C; Abu Hilal M; Higginson AP; Armstrong T; Smith A; Scarsbrook A; McKay C; Carter R; Sutcliffe RP; Bramhall S; Kocher HM; Cunningham D; Pereira SP; Davidson B; Chang D; Khan S; Zealley I; Sarker D; Al Sarireh B; Charnley R; Lobo D; Nicolson M; Halloran C; Raraty M; Sutton R; Vinjamuri S; Evans J; Campbell F; Deeks J; Sanghera B; Wong WL; Neoptolemos JP
Health Technol Assess; 2018 Feb; 22(7):1-114. PubMed ID: 29402376
[TBL] [Abstract][Full Text] [Related]
30. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing.
Wong CK; Lam CL; Wan YF; Fong DY
BMC Cancer; 2015 Oct; 15():705. PubMed ID: 26471036
[TBL] [Abstract][Full Text] [Related]
32. Extensive Computed Tomography versus Limited Screening for Detection of Occult Cancer in Unprovoked Venous Thromboembolism: A Multicenter, Controlled, Randomized Clinical Trial.
Prandoni P; Bernardi E; Valle FD; Visonà A; Tropeano PF; Bova C; Bucherini E; Islam MS; Piccioli A
Semin Thromb Hemost; 2016 Nov; 42(8):884-890. PubMed ID: 27764880
[TBL] [Abstract][Full Text] [Related]
33. Screening for Malignancy in Patients With Unprovoked Venous Thromboembolism: A Single-Center Retrospective Case Series.
Barrett A; Kevane B; Hall P; Ní Áinle F; Breslin T
Clin Appl Thromb Hemost; 2017 Oct; 23(7):735-739. PubMed ID: 27443696
[TBL] [Abstract][Full Text] [Related]
34. FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial.
de Koster EJ; Vriens D; van Aken MO; Dijkhorst-Oei LT; Oyen WJG; Peeters RP; Schepers A; de Geus-Oei LF; van den Hout WB;
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3452-3469. PubMed ID: 35435497
[TBL] [Abstract][Full Text] [Related]
35. Should mediastinoscopy actually be incorporated into the FDG PET strategy for patients with non-small cell lung carcinoma?
Hayashi K; Abe K; Yano F; Watanabe S; Iwasaki Y; Kosuda S
Ann Nucl Med; 2005 Jul; 19(5):393-8. PubMed ID: 16164196
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission.
Huntington SF; Svoboda J; Doshi JA
J Clin Oncol; 2015 May; 33(13):1467-74. PubMed ID: 25823735
[TBL] [Abstract][Full Text] [Related]
37. Use of a decision analysis model to assess the medicoeconomic implications of FDG PET imaging in diagnosing a solitary pulmonary nodule.
Lejeune C; Al Zahouri K; Woronoff-Lemsi MC; Arveux P; Bernard A; Binquet C; Guillemin F
Eur J Health Econ; 2005 Sep; 6(3):203-14. PubMed ID: 15834623
[TBL] [Abstract][Full Text] [Related]
38. Utility of additional abdominopelvic CT in detecting occult cancer in patients with unprovoked venous thromboembolism.
Vaidyanathan S; Walsh J; Cliffe H; Saleem N; Weston MJ; Lowe AS; Chowdhury FU
Clin Radiol; 2016 Jun; 71(6):501-6. PubMed ID: 27005017
[TBL] [Abstract][Full Text] [Related]
39. Extensive screening for occult malignancy in unprovoked venous thromboembolism: A meta-analysis.
Zhou M; Zhang L; Ding Y; Wang Y; Yan D; Lin C; Shi Z; Fu W
Thromb Res; 2017 Sep; 157():147-153. PubMed ID: 28753478
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
